Research evidence / Overview of Studies for Excenel
Evidence for Use in Bovine Respiratory Disease (BRD) and Swine Pneumonia
The primary research forming the regulatory evidence base for Ceftiofur in respiratory infections consists of controlled field trials. These trials were evaluated in research exploring how outcomes related to systemic or functional imbalance change over time in cattle with Bovine Respiratory Disease (BRD) and in pigs with bacterial pneumonia. In these investigations, Ceftiofur was observed in large populations of animals and often included comparative arms, such as non-treatment controls or other active agents. Researchers focused on measuring clinical outcomes, such as changes in fever and scoring systems for respiratory distress, which are relevant in trials assessing short-term or episodic symptom patterns.
The findings describe patterns observed in the studies over the short treatment period and immediate follow-up. For instance, some trials reported measurements of the rate of clinical recovery (or non-recovery) and described how parameters like high body temperature and signs of depression were monitored in the observed populations. In swine, research explored how the medicine was associated with sustained cure rates and changes in pre-defined symptom scores. These studies contribute to the broader evidence landscape by documenting the immediate symptomatic patterns when the medicine is used in research scenarios examining temporary physiological imbalance.
However, there are areas where the certainty remains low. Regulatory records note that a direct, consistent relationship between the drug concentration in plasma and the clinical effectiveness has not been fully established for all official uses. Furthermore, research is ongoing regarding the potential for the selection of antimicrobial-resistant bacterial strains in the treated populations, which was observed in some studies.
Evidence for Use in Localized and Systemic Cattle Infections
The medicine was studied for two other key cattle indications: Acute Bovine Interdigital Necrobacillosis (Foot Rot) and Acute Postpartum Metritis. For these conditions, the research structure primarily involved Controlled Clinical Trials. These studies examined outcomes linked to inflammatory or irritative states and outcomes describing episodic or acute changes, such as acute lameness scores in Foot Rot cases and the reduction of fever and abnormal discharge in Metritis. These investigations were conducted during periods of increased symptom activity in the affected cattle.
For Foot Rot, the findings indicate patterns related to the clinical cure rates and changes in the severity of lameness scores over the short follow-up duration. In Metritis, trials reported measurements of clinical resolution, defined by the absence of systemic signs like fever. However, research exploring short-term symptom changes in Metritis also noted a naturally high rate of spontaneous resolution of clinical signs in untreated control groups, which means subgroup findings are uncertain when isolating the treatment-specific effect.
Research shows that for localized infections like Foot Rot, the data for certain groups remain insufficient regarding the link between drug concentrations in the bloodstream and the monitored treatment response at the site of the tissue infection. Furthermore, for Metritis, the evidence structure sometimes indicates that the drug was evaluated in specific research scenarios, such as when other initial treatments had failed, meaning the findings reflect this specific treatment context.
Research on Defined Time Intervals and Follow-Up Duration
The evidence base for Ceftiofur primarily consists of studies that focused on short-term measures of clinical recovery, generally within the first 3 to 7 days after starting treatment. The clinical trials then extended the observation to a typical intermediate-term follow-up, which usually concluded around Day 14 or Day 28. This evidence structure means the follow-up durations were limited to monitoring the acute disease episode and immediate recovery phase.
Research examined the patterns of the measured clinical parameters during these short, defined time intervals. However, there is limited information for long-term outcomes or how the treatment might affect the animal's overall health or future disease susceptibility far beyond the final study assessment. The existing data provide insight into short-term changes, but long-term effects are not fully established, meaning the evidence highlights what is known — and what is still uncertain about sustained health outcomes.
Populations Studied and Unique Treatment Contexts
The research has been primarily conducted in the main populations where the medicine is used: beef and dairy cattle and swine (pigs). Studies monitored the change in measured parameters in young animals, such as calves and piglets, which are often the groups most susceptible to severe respiratory illness. Therefore, the results apply only to the populations studied and cannot be generalized beyond them.
Crucially, the research explored the use of the medicine in unique research scenarios, such as when pigs were also infected with respiratory viruses like PRRSV. In these complex contexts, studies explored how the presence of the co-infection was associated with an altered drug concentration profile in the animals' systems. This research contributes to the broader evidence landscape by showing that the drug's concentration profile may be altered when evidence derived from settings with varying symptom burdens is considered.
Evidence Quality and Areas Where Certainty Remains Low
The regulatory evidence supporting Ceftiofur's use in the main respiratory indications is considered High because it is based on multiple large, randomized, controlled field trials. For other indications like Metritis and Foot Rot, the evidence level is classified as Moderate. This variation means the evidence quality varies across studies depending on the specific disease being evaluated in research.
The main research limitation frame is that the sample sizes were modest in some of the initial approval trials, and the follow-up durations were limited to the short term, restricting insights into long-term outcomes. Furthermore, the question of a direct link between the drug levels in the blood and the clinical success remains an area where certainty remains low for localized infections. This means the research provides context but does not determine whether an individual animal will respond similarly under all possible field conditions.
Key Studies & References
Veterinary Medicinal Product EXCENEL Flow 50 mg/ml suspension for injection for pigs and cattle - Summary of Product Characteristics (SPC)
